Harmony Biosciences Holdings, Inc. (HRMY) Fundamental Analysis: Bull vs. Bear Case

HRMY

Harmony Biosciences Holdings, Inc.

Fundamental data last updated:August 24, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

VALUATION

P/E

12.50 Market Cap ($M USD)

$1.82B

Forward P/E

5.82 PEG

0.05 PRICE TO SALES

2.03 PRICE TO BOOK

2.00 EV / EBITDA

6.17 5-Year Average P/E

Free Cash Flow Yield

18.75%

DCF Value

$117.84

Graham Number

$29.87

Price to FCF

5.33 EV to FCF

4.21 Earnings Yield

8.00%

FCF Yield

18.75%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.52

Next Year EPS Growth Estimate

$5.41

Next Year Revenue Growth Estimate

$1.26B

Return on Equity (ROE)

17.19%

FREE CASH FLOW

Operating Margin

21.08%

Debt-to-Equity

0.28 Piotroski F-Score

5 Altman Z-Score

4.95 Return on Invested Capital (ROIC)

17.97%

Current Ratio

3.58 Quick Ratio

3.56 Net Debt to EBITDA

-1.64

Interest Coverage

13.49 Gross Profit margin

76.55%

FCF PER SHARE

$5.91

REVENUE PER SHARE

$15.55

Gainseekers Quantitative Analysis

Summary

Harmony Biosciences Holdings, Inc. appears to be dramatically undervalued based on its DCF Value, which towers over recent pricing. The Forward P/E of 5.71 and an Earnings Yield of 8.13% suggest a compelling growth opportunity, while the Altman Z-score of 4.94 indicates strong financial stability. The market seems to be mispricing this stock, ignoring its robust earnings potential and safety. With a PEG Forward ratio of just 0.05, the company is priced for significant growth, making it an attractive target for value investors.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Harmony Biosciences is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The healthcare industry is increasingly integrating tech solutions, and this company stands to benefit from these innovations. Its adaptability to modern tech shifts could enhance its competitive edge and operational efficiency.

The Bull Case

For the value-driven investor, Harmony Biosciences offers a compelling narrative. With an ROIC of 17.97% and a Free Cash Flow Yield of 19.05%, the company demonstrates exceptional capital efficiency and cash generation. The Piotroski F-Score of 5 and an operating margin of 21.08% further underscore its operational prowess. These metrics suggest strong pricing power and a disciplined management team, making it an attractive buy for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, Harmony Biosciences is not without risks. The Price/Book ratio of 1.97 and Price/Sales of 1.99 suggest the stock might not be as cheap as it seems on a book value basis. Additionally, the stock's proximity to its 52-week high could indicate a potential overextension, posing a risk of a pullback. Investors should remain cautious of these valuation metrics, which could signal a less favorable entry point.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$43.00

Institutional Ownership %

1-Year Beta

0.97 Insider Buying % (6 Mo)

Distance to 52-Week High

29.79%

Distance to 52-Week Low

18.96%

EARNINGS SURPRISE %

-27.63%

50-DAY SMA

$29.77

200-DAY SMA

$32.58

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.